Cargando…

Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study

OBJECTIVES: Early in vitro studies have suggested that hydroxychloroquine (HCQ) is a potentially useful drug against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. This study was conducted to determine whether HCQ had a preventive effect on coronavirus disease 2019 (COVID-1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Sun-Young, Kim, Myo-Song, Kim, Min-Chul, Choi, Seong-Ho, Chung, Jin-Won, Choi, Sang Tae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832641/ https://www.ncbi.nlm.nih.gov/pubmed/33316402 http://dx.doi.org/10.1016/j.cmi.2020.12.003

Ejemplares similares

Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study
por: Gentry, Chris A, et al.
Publicado: (2020)

Development of SARS-CoV-2 infection in patients with rheumatic conditions on hydroxychloroquine monotherapy vs. patients without rheumatic conditions: A retrospective, propensity-matched cohort study
por: Gentry, Chris A., et al.
Publicado: (2023)

Hydroxychloroquine in rheumatic autoimmune disorders and beyond
por: Nirk, Eliise Laura, et al.
Publicado: (2020)

Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
por: Mehta, Sudhir, et al.
Publicado: (2020)

Clinical and radiological findings of adult hospitalized patients with community-acquired pneumonia from SARS-CoV-2 and endemic human coronaviruses
por: Baek, Moon Seong, et al.
Publicado: (2021)

Recurrent Kikuchi's Disease Treated by Hydroxychloroquine
por: Hyun, Miri, et al.
Publicado: (2016)

Evidence of Exposure to SARS-CoV-2 in Dogs and Cats from Households and Animal Shelters in Korea
por: Bae, Da-Yun, et al.
Publicado: (2022)

Immune Responses against the Omicron Variant of SARS-CoV-2 after a Third Dose of COVID-19 Vaccine in Patients Living with Human Immunodeficiency Virus (PLWH): Comparison with Healthcare Workers
por: Park, Joung Ha, et al.
Publicado: (2022)

Incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine
por: Singh, Dilpreet K, et al.
Publicado: (2019)

Relationship between SARS-CoV-2 antibody titer and the severity of COVID-19
por: Park, Joung Ha, et al.
Publicado: (2022)

Duration of Culturable SARS-CoV-2 in Hospitalized Patients with Covid-19
por: Kim, Min-Chul, et al.
Publicado: (2021)

Antibody kinetics and serologic profiles of SARS-CoV-2 infection using two serologic assays
por: Kweon, Oh Joo, et al.
Publicado: (2020)

Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019
por: Kim, Ji-Won, et al.
Publicado: (2022)

Hydroxychloroquine Does Not Increase the Risk of Cardiac Arrhythmia in Common Rheumatic Diseases: A Nationwide Population-Based Cohort Study
por: Lo, Chien-Hsien, et al.
Publicado: (2021)

Has the door closed on hydroxychloroquine for SARS-COV-2?
por: Paul, Mical
Publicado: (2021)

Hyperglycémie, hydroxychloroquine et SARS-CoV-2
por: Ilias, Ioannis, et al.
Publicado: (2021)

The relationship between SARS-CoV-2 antibody titers and the severity of COVID-19
por: Park, Joung Ha, et al.
Publicado: (2021)

Adverse drug reactions of hydroxychloroquine: Analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data
por: Grandvuillemin, Aurélie, et al.
Publicado: (2020)

Impact of hydroxychloroquine used as DMARD on SARS-CoV-2 tests and infection evolution in a population of 871 patients with inflammatory rheumatic and musculoskeletal diseases
por: Trefond, Ludovic, et al.
Publicado: (2021)

Comment on: Incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine
por: Pareek, Anil, et al.
Publicado: (2019)

Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial
por: Abella, Benjamin S., et al.
Publicado: (2020)

Chronic Rheumatism and the Pre-Rheumatic State
Publicado: (1933)

Analysis of pre- and intraoperative clinical for successful operating room extubation after living donor liver transplantation: a retrospective observational cohort study
por: Chae, Min Suk, et al.
Publicado: (2019)

Evaluation of rapid SARS-CoV-2 antigen tests, AFIAS COVID-19 Ag and ichroma COVID-19 Ag, with serial nasopharyngeal specimens from COVID-19 patients
por: Kweon, Oh Joo, et al.
Publicado: (2021)

A simple approach to preserve keratinized mucosa around implants using a pre-fabricated implant-retained stent: a report of two cases
por: Park, Jung-Chul, et al.
Publicado: (2010)

Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases
por: dos Reis Neto, Edgard Torres, et al.
Publicado: (2020)

Comment on: incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine: reply
por: Singh, Dilpreet K, et al.
Publicado: (2019)

Retrospective study on the effects of immunosuppressive therapy in uveitis associated with rheumatic diseases in Korea
por: Lee, Sang Yeob, et al.
Publicado: (2011)

Exposure to ambient fine particulate matter is associated with changes in fasting glucose and lipid profiles: a nationwide cohort study
por: Shin, Woo-young, et al.
Publicado: (2020)

Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial
por: Rajasingham, Radha, et al.
Publicado: (2020)

Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil
por: Pileggi, Gecilmara Salviato, et al.
Publicado: (2021)

Are hydroxychloroquine and chloroquine effective in the treatment of SARS-COV-2 (COVID-19)?
por: Wright, Christopher, et al.
Publicado: (2020)

Hydroxychloroquine: mechanism of action inhibiting SARS-CoV2 entry.
por: Yuan, Zixuan, et al.
Publicado: (2020)

Impact of Hydroxychloroquine on Antibody Responses to the SARS-CoV-2 Coronavirus
por: de Miranda Santos, Isabel Kinney Ferreira, et al.
Publicado: (2020)

First evaluation of hydroxychloroquine recommendations in treating SARS-CoV-2
por: Roussel, Y., et al.
Publicado: (2020)

Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2
por: Ingraham, Nicholas E., et al.
Publicado: (2020)

Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load
por: Nguyen, Tuan V.
Publicado: (2021)

Interpreting the impact of hydroxychloroquine prophylaxis on SARS-CoV-2 infection
por: Yadav, Reetika Malik, et al.
Publicado: (2021)

Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study
por: Kamstrup, Peter, et al.
Publicado: (2021)

Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians
por: Schreiber, Karen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vet7gnjtirt7lf1t49c4an2c9i